Publicacións en colaboración con investigadores/as de Institut d'Investigacions Biomèdiques August Pi i Sunyer (31)

2024

  1. An atlas of cells in the human tonsil

    Immunity, Vol. 57, Núm. 2, pp. 379-399.e18

  2. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

    Nature Communications, Vol. 15, Núm. 1

  3. PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

    Leukemia

2023

  1. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  2. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Leukemia, Vol. 37, Núm. 2, pp. 339-347

  3. Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)

    Bone Marrow Transplantation

2022

  1. Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients

    Haematologica, Vol. 107, Núm. 3, pp. 593-603

  2. Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer

    Cancers, Vol. 14, Núm. 16

  3. Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma

    Leukemia, Vol. 36, Núm. 2, pp. 583-587

  4. Landscape and clinical significance of long noncoding RNAs involved in multiple myeloma expressed fusion transcripts

    American Journal of Hematology

  5. NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial

    Cancers, Vol. 14, Núm. 20

2021

  1. Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma

    Leukemia, Vol. 35, Núm. 5, pp. 1438-1450

  2. Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation

    Nature Communications, Vol. 12, Núm. 1

  3. Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma

    Leukemia, Vol. 35, Núm. 10, pp. 3012-3016

2020

  1. Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma

    Genome Research, Vol. 30, Núm. 9, pp. 1217-1227

  2. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

    Blood, Vol. 136, Núm. 2, pp. 199-209

  3. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792

  4. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

    Blood Cancer Journal, Vol. 10, Núm. 2

  5. The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation

    Haematologica, Vol. 105, Núm. 3, pp. 774-783

  6. The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome

    Nature Cancer, Vol. 1, Núm. 11, pp. 1066-1081